Liafensine, a new triple reuptake inhibitor, is effective and well tolerated in carriers of the ANK3 gene with treatment-resistant depression, according to a phase 2b trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/first-class-antidepressant-effective-ank3-positive-trd-2025a1000oa6?src=rss
Author :
Publish date : 2025-09-15 06:55:00
Copyright for syndicated content belongs to the linked Source.
